E. Slosberg

发表

Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells.

B. C. Wong, S. Yuen, I. Weinstein, 2000, Gastroenterology.

The protein kinase C β–specific inhibitor LY379196 blocks TPA‐induced monocytic differentiation of HL60 cells the protein kinase C β–specific inhibitor LY379196 blocks TPA‐induced monocytic differentiation of HL60 cells

I. Weinstein, A. Ikui, M. Jirousek, 2000, Molecular carcinogenesis.

Chondrocyte cluster formation in agarose cultures as a functional assay to identify genes expressed in osteoarthritis

J. Quintavalla, S. Uziel-Fusi, S. Daouti, 2005, Journal of cellular physiology.

The α isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21cip1 induction in HC11 mammary epithelial cells

I. Schieren, M. Klein, I. Weinstein, 1999, Oncogene.

Signature program: a platform of basket trials

D. Berry, S. Stein, F. Meric-Bernstam, 2018, Oncotarget.

Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family.

Y. Doki, C. Lima, M. Klein, 1998, Experimental cell research.

Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression.

M. Kaleko, S. Connelly, U. Desai, 2001, Diabetes.

Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.

L. Beckett, J. Riess, K. Kelly, 2015 .

Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells

I. Schieren, I. Weinstein, J. Soh, 1999, Oncogene.

Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice

H. Hibshoosh, I. Weinstein, Yu-jing Zhang, 1999, Oncogene.

Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-β1-dependent pathway

I. Weinstein, B. Wong, H. Kung, 2002, Oncogene.

Treatment of type 2 diabetes by adenoviral-mediated overexpression of the glucokinase regulatory protein.

M. Kaleko, S. Connelly, U. Desai, 2001, Diabetes.

The Signature Program: Bringing the Protocol to the Patient

S. Stein, C. Lebedinsky, A. Salvado, 2015, Clinical pharmacology and therapeutics.

Differential subtraction chain, a method for identifying differences in genomic DNA and mRNA.

M. Becich, J. Puc, Yuan Yao, 1999, Nucleic acids research.

Ectopic expression of a mutant form of PKCα originally found in human tumors: aberrant subcellular translocation and effects on growth control

C. Prévostel, D. Joubert, V. Alvaro, 1997, Oncogene.

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.

K. Kelly, L. Nadauld, J. Grilley-Olson, 2016 .

Interactions of retinol with binding proteins: studies with retinol-binding protein and with transthyretin.

S. Scarlata, N. Noy, E. Slosberg, 1992, Biochemistry.

Successful implementation of a novel trial model: The Signature program.

L. Nadauld, A. Alva, S. Piha-Paul, 2015 .